|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCL18 |
Gene summary for CCL18 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCL18 | Gene ID | 6362 |
| Gene name | C-C motif chemokine ligand 18 | |
| Gene Alias | AMAC-1 | |
| Cytomap | 17q12 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P55774 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6362 | CCL18 | C21 | Human | Oral cavity | OSCC | 4.02e-13 | 6.18e-01 | 0.2678 |
| 6362 | CCL18 | C30 | Human | Oral cavity | OSCC | 5.28e-20 | 6.71e-01 | 0.3055 |
| 6362 | CCL18 | C57 | Human | Oral cavity | OSCC | 3.17e-05 | 1.95e-01 | 0.1679 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003461218 | Oral cavity | OSCC | response to tumor necrosis factor | 143/7305 | 253/18723 | 1.09e-08 | 2.23e-07 | 143 |
| GO:007135618 | Oral cavity | OSCC | cellular response to tumor necrosis factor | 128/7305 | 229/18723 | 1.49e-07 | 2.49e-06 | 128 |
| GO:00343417 | Oral cavity | OSCC | response to interferon-gamma | 81/7305 | 141/18723 | 6.77e-06 | 7.43e-05 | 81 |
| GO:00192214 | Oral cavity | OSCC | cytokine-mediated signaling pathway | 222/7305 | 472/18723 | 2.02e-04 | 1.35e-03 | 222 |
| GO:00713465 | Oral cavity | OSCC | cellular response to interferon-gamma | 65/7305 | 118/18723 | 2.83e-04 | 1.79e-03 | 65 |
| GO:005090010 | Oral cavity | OSCC | leukocyte migration | 176/7305 | 369/18723 | 3.80e-04 | 2.31e-03 | 176 |
| GO:004308710 | Oral cavity | OSCC | regulation of GTPase activity | 165/7305 | 348/18723 | 7.94e-04 | 4.27e-03 | 165 |
| GO:00603269 | Oral cavity | OSCC | cell chemotaxis | 146/7305 | 310/18723 | 2.13e-03 | 9.80e-03 | 146 |
| GO:00705556 | Oral cavity | OSCC | response to interleukin-1 | 73/7305 | 143/18723 | 2.23e-03 | 1.00e-02 | 73 |
| GO:00305959 | Oral cavity | OSCC | leukocyte chemotaxis | 110/7305 | 230/18723 | 3.86e-03 | 1.58e-02 | 110 |
| GO:00713473 | Oral cavity | OSCC | cellular response to interleukin-1 | 58/7305 | 113/18723 | 5.14e-03 | 2.01e-02 | 58 |
| GO:00434107 | Oral cavity | OSCC | positive regulation of MAPK cascade | 213/7305 | 480/18723 | 8.71e-03 | 3.16e-02 | 213 |
| GO:00703716 | Oral cavity | OSCC | ERK1 and ERK2 cascade | 150/7305 | 330/18723 | 9.47e-03 | 3.38e-02 | 150 |
| GO:007162110 | Oral cavity | OSCC | granulocyte chemotaxis | 62/7305 | 125/18723 | 1.02e-02 | 3.52e-02 | 62 |
| GO:00703724 | Oral cavity | OSCC | regulation of ERK1 and ERK2 cascade | 140/7305 | 309/18723 | 1.34e-02 | 4.46e-02 | 140 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| CCL18 | ACKR1 | CCL18_ACKR1 | CCL | Breast | Healthy |
| CCL18 | ACKR1 | CCL18_ACKR1 | CCL | Breast | IDC |
| CCL18 | ACKR1 | CCL18_ACKR1 | CCL | Cervix | CC |
| CCL18 | ACKR1 | CCL18_ACKR1 | CCL | Cervix | Precancer |
| CCL18 | ACKR1 | CCL18_ACKR1 | CCL | HNSCC | OSCC |
| CCL18 | ACKR1 | CCL18_ACKR1 | CCL | HNSCC | Precancer |
| CCL18 | ACKR1 | CCL18_ACKR1 | CCL | Lung | AAH |
| CCL18 | ACKR1 | CCL18_ACKR1 | CCL | Lung | AIS |
| CCL18 | ACKR1 | CCL18_ACKR1 | CCL | Lung | IAC |
| CCL18 | ACKR1 | CCL18_ACKR1 | CCL | Lung | Precancer |
| CCL18 | ACKR1 | CCL18_ACKR1 | CCL | THCA | ADJ |
| CCL18 | ACKR1 | CCL18_ACKR1 | CCL | THCA | Cancer |
| CCL18 | ACKR1 | CCL18_ACKR1 | CCL | THCA | Precancer |
| CCL18 | ACKR1 | CCL18_ACKR1 | CCL | THCA | PTC |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCL18 | SNV | Missense_Mutation | rs540060026 | c.199N>T | p.Arg67Trp | p.R67W | P55774 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCL18 | SNV | Missense_Mutation | novel | c.32N>C | p.Leu11Pro | p.L11P | P55774 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCL18 | SNV | Missense_Mutation | rs374733570 | c.250N>A | p.Asp84Asn | p.D84N | P55774 | protein_coding | tolerated(0.11) | benign(0.332) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCL18 | SNV | Missense_Mutation | novel | c.259C>A | p.Leu87Met | p.L87M | P55774 | protein_coding | tolerated(0.18) | possibly_damaging(0.863) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| CCL18 | SNV | Missense_Mutation | rs778538949 | c.200N>A | p.Arg67Gln | p.R67Q | P55774 | protein_coding | deleterious(0.04) | possibly_damaging(0.477) | TCGA-EY-A1GK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CCL18 | SNV | Missense_Mutation | novel | c.225N>C | p.Lys75Asn | p.K75N | P55774 | protein_coding | tolerated(0.06) | benign(0.079) | TCGA-EY-A210-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| CCL18 | SNV | Missense_Mutation | novel | c.16G>T | p.Ala6Ser | p.A6S | P55774 | protein_coding | tolerated(0.06) | possibly_damaging(0.505) | TCGA-55-7576-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | alimta | CR |
| CCL18 | SNV | Missense_Mutation | novel | c.43N>G | p.Met15Val | p.M15V | P55774 | protein_coding | tolerated(0.6) | benign(0) | TCGA-80-5611-01 | Lung | lung adenocarcinoma | Male | Unknown | I/II | Unknown | Unknown | SD |
| CCL18 | SNV | Missense_Mutation | novel | c.46N>T | p.Ala16Ser | p.A16S | P55774 | protein_coding | tolerated(0.2) | benign(0.069) | TCGA-BR-4357-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
| CCL18 | SNV | Missense_Mutation | novel | c.266C>T | p.Ala89Val | p.A89V | P55774 | protein_coding | deleterious(0) | probably_damaging(0.931) | TCGA-BR-7851-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 6362 | CCL18 | DRUGGABLE GENOME | IMMUNOMODULATORS | 12161279 | ||
| 6362 | CCL18 | DRUGGABLE GENOME | LD78 | 9233607 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |